| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.0006-341X.2001.00886.X |
| P698 | PubMed publication ID | 11550941 |
| P894 | zbMATH Open document ID | 1209.62180 |
| P2093 | author name string | H Schäfer | |
| H H Müller | |||
| P433 | issue | 3 | |
| P6104 | maintained by WikiProject | WikiProject Mathematics | Q8487137 |
| P304 | page(s) | 886-891 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Biometrics | Q2025724 |
| P1476 | title | Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches | |
| P478 | volume | 57 |
| Q33514894 | A Bayesian adaptive design for two-stage clinical trials with survival data |
| Q42960376 | A Bayesian adaptive design with biomarkers for targeted therapies |
| Q90718814 | A pragmatic, adaptive clinical trial design for a rare disease: The FOcal Cerebral Arteriopathy Steroid (FOCAS) trial |
| Q40009132 | A simple and flexible graphical approach for adaptive group-sequential clinical trials |
| Q57305770 | Adaptive Budgets in Clinical Trials |
| Q44711945 | Adaptive Methods: Telling “The Rest of the Story” |
| Q42753983 | Adaptive Multivariate Global Testing |
| Q26824359 | Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency |
| Q42250318 | Adaptive designs for subpopulation analysis optimizing utility functions |
| Q82060078 | Adaptive dose‐finding: Proof of concept with type I error control |
| Q37162794 | Adaptive enrichment designs for clinical trials |
| Q89670825 | Adaptive multiarm multistage clinical trials |
| Q45358679 | Adaptive trial design: its growing role in clinical research and implications for pharmacists |
| Q38793656 | Bayesian adaptive design: improving the effectiveness of monitoring of the Great Barrier Reef. |
| Q34367570 | Choosing inclusion criteria that minimize the time and cost of clinical trials |
| Q35182733 | Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives |
| Q36003964 | Comparison of 6% hydroxyethyl starch and 5% albumin for volume replacement therapy in patients undergoing cystectomy (CHART): study protocol for a randomized controlled trial. |
| Q42926272 | Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility |
| Q30883035 | Data-Driven Analysis Strategies for Proportion Studies in Adaptive Group Sequential Test Designs |
| Q33621941 | Design and Organization of the Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT) Trial: a factorial trial evaluating the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity |
| Q26749027 | Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure |
| Q36700721 | Early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury (The ELAIN-Trial): study protocol for a randomized controlled trial |
| Q33437253 | Evidence synthesis as the key to more coherent and efficient research |
| Q35946307 | Flexible design for following up positive findings |
| Q38280824 | Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial |
| Q44913535 | Internal pilots for observational studies |
| Q58776805 | Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial |
| Q40344979 | Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look. |
| Q28652785 | Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications |
| Q36960891 | Methodology guideline for clinical studies investigating traditional Chinese medicine and integrative medicine: executive summary |
| Q36285351 | Modelling and simulation in the development and use of anti-cancer agents: an underused tool? |
| Q92880434 | Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials |
| Q58575622 | Optimal promising zone designs |
| Q38497200 | Precision of maximum likelihood estimation in adaptive designs |
| Q33380428 | Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. |
| Q35919624 | Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials |
| Q36129605 | Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience |
| Q38963341 | Sample size reassessment for a two-stage design controlling the false discovery rate |
| Q62589002 | Some Characteristics of the Varying-Stage Adaptive Phase II/III Clinical Trial Design |
| Q78466414 | Strategies for changing the test statistic during a clinical trial |
| Q35744785 | The advantages and disadvantages of adaptive designs for clinical trials |
| Q38380750 | Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. |
| Q45194501 | Understanding the FDA Guidance on Adaptive Designs: Historical, Legal, and Statistical Perspectives |
Search more.